BFRA - Biofrontera AG
| Previous Close | 9.90 |
| Open | 9.90 |
| Bid | 10.23 x 1400 |
| Ask | 14.50 x 1400 |
| Day's Range | 9.90 - 9.90 |
| 52 Week Range | 9.00 - 18.32 |
| Volume | 108 |
| Avg. Volume | 469 |
| Market Cap | 244M |
| Beta (5Y Monthly) | 0.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.76 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.50 |
- GlobeNewswire
Christopher Pearson appointed new Chief Commercial Officer at US subsidiary Biofrontera Inc.
Leverkusen, Germany, Dec. 13, 2019 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced today.
- GlobeNewswire
Biofrontera to Participate in Upcoming Investor Conferences
Leverkusen, Germany, Nov. 22, 2019 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced.
- GlobeNewswire
Biofrontera Reports Third Quarter 2019 Financial Results and Revises Guidance
Leverkusen, Germany, Nov. 19, 2019 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced.
- GlobeNewswire
Biofrontera Announces Conference Call on November 19, 2019 to Discuss Third Quarter 2019 Financial Results
Leverkusen, Germany, Nov. 06, 2019 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be.
- GlobeNewswire
Biofrontera Receives Award at Fall Clinical Dermatology Conference 2019
Leverkusen, Germany, Oct. 23, 2019 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, was presented.
- GlobeNewswire
Biofrontera reports preliminary unaudited sales revenue for the first nine months of 2019
Leverkusen, Germany, Oct. 10, 2019 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or the “Biofrontera-group”), an international.
- GlobeNewswire
Biofrontera to present at the Baader Investment Conference
Leverkusen, Germany, Sept. 17, 2019 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced that.
- GlobeNewswire
Biofrontera Files Label Extension for Ameluz® in EU to include Treatment of Actinic Keratosis on Extremities and Trunk/Neck
Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, has filed a label extension for Ameluz® with the European Medicines Agency (EMA) on August 28, 2019 to include treatment of mild and moderate actinic keratosis (AK) of the extremities and trunk/neck with photodynamic therapy (PDT).
- GlobeNewswire
Biofrontera to participate at the Lake Street Capital Markets 2019 Best Ideas Growth (BIG) Conference
Leverkusen, Germany, Sept. 05, 2019 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be.
- GlobeNewswire
Biofrontera shows robust growth during first six months of 2019
Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its results for the first six months ended June 30, 2019. At the same time, Biofrontera provided an update on recent business developments. Due to the one-time positive effect of the badwill resulting from the purchase price allocation of Cutanea Life Sciences, Inc. (Cutanea) Biofrontera reported a positive net result of EUR 8.6 million for the reporting period.
- GlobeNewswire
Biofrontera Announces Conference Call on August 27, 2019 to Discuss Half-year 2019 Financial Results
Leverkusen, Germany, Aug. 14, 2019 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be.
- GlobeNewswire
Biofrontera provides update on Cutanea integration
Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company, provides an update on the integration progress of Cutanea Life Sciences, Inc. (“Cutanea”). On March 25, 2019, Biofrontera Inc. through its wholly owned subsidiary Biofrontera Newderm LLC, acquired 100% of the stock of Cutanea, a specialty pharmaceutical company focused on dermatology products, from Maruho Co., Ltd. (“Maruho”). At the time of the acquisition, Maruho had agreed to cover any restructuring expenses as well as all other expenses during the three-month integration period, which ended on June 25, 2019, as well as to indemnify Biofrontera and Cutanea from any liabilities relating to or arising from the period prior to the closing.
- GlobeNewswire
Results of the voluntary partial tender offers
Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, informs about the conclusion of the voluntary public partial tender offers of Maruho Deutschland GmbH as well as Deutsche Balaton Biotech AG and DELPHI Unternehmensberatung Aktiengesellschaft ("Offers"). On April 15, 2019, Maruho Deutschland GmbH published an offer to the shareholders of Biofrontera AG to acquire up to 4,322,530 of its registered non-par value shares in Biofrontera AG for a cash payment of EUR 6.60 per Biofrontera share.
- GlobeNewswire
Annual General Meeting of Biofrontera AG: Biofrontera Management Board approved by large majority
Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced the results of the Annual General Meeting held on 10 July 2019. The shareholders present represented 75.88% of the registered share capital. The shareholders approved the agenda items proposed by the Management Board and Supervisory Board (published in the Federal Gazette on June 3, 2019) with a large majority.
- GlobeNewswire
All Biofrontera Management Board members intend to fully accept the partial tender offer by Maruho Deutschland GmbH for their shares
Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announces that the members of the Management Board, Prof. Dr. Hermann Lübbert, Thomas Schaffer and Christoph Dünwald, intend to tender all of their personally held Biofrontera AG shares to the partial tender offer by Maruho Deutschland GmbH. The Management Board would like to help Maruho Deutschland GmbH to successfully complete its offer and serve as an example for other shareholders.
- GlobeNewswire
Biofrontera to Present at Two Upcoming Investor Conferences
Leverkusen, Germany, June 12, 2019 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced.
- GlobeNewswire
Biofrontera nominates new candidate for the Supervisory Board
Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced that the agenda for the Annual General Meeting to be held on July 10, 2019 has been published. The Supervisory Board proposes that Prof. Dr. Franca Ruhwedel be elected to the Supervisory Board as successor to Hansjörg Plaggemars, who was dismissed as a member of the Supervisory Board by court order as of March 22, 2019. "As Professor of Finance and Accounting at the Rhine-Waal University of Applied Sciences, she has sound knowledge of accounting and risk management, which is very valuable for her work on the Supervisory Board.
- ACCESSWIRE
Biofrontera AG to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 29, 2019 / Biofrontera AG (NASDAQ: BFRA ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 29, 2019 at 2:00 PM Eastern Time. ...
- GlobeNewswire
Biofrontera Announces Conference Call on May 29, 2019 to Discuss First Quarter 2019 Financial Results
Leverkusen, Germany, May 16, 2019 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be.
- GlobeNewswire
Biofrontera Reports Full Year 2018 Financial Results
Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the full year ended December 31, 2018 and provided an update on recent operational and clinical developments.
- GlobeNewswire
Biofrontera AG to hold extraordinary shareholders’ meeting on 15 May 2019
Leverkusen, Germany, April 26, 2019 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today.
- GlobeNewswire
Biofrontera reports further positive results from the phase III trial with Ameluz® for photodynamic therapy of actinic keratoses on the extremities and trunk/neck
Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports positive results for the secondary endpoints of its Phase III clinical trial evaluating the safety and efficacy of conventional photodynamic therapy (PDT) with Ameluz® in combination with the BF-RhodoLED® lamp for the treatment of actinic keratoses (AK) on the extremities or trunk/neck. In line with the result for the primary endpoint of the study (see ad hoc report dated March 20, 2019), which showed a mean lesion clearance rate per patient’s side of 86% for Ameluz® compared to 33% for placebo, significant superiority of Ameluz® was demonstrated for all secondary parameters investigated. In patients treated on the extremities, mean lesion clearance rates per patient’s side were also 84% with Ameluz® compared to 27% with placebo.
- GlobeNewswire
Biofrontera Announces Conference Call on April 29, 2019 to Discuss 2018 Financial Results
Leverkusen, Germany, April 16, 2019 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be.
- GlobeNewswire
Biofrontera reports preliminary unaudited sales revenue for the first three months of 2019
Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports preliminary unaudited revenue for the first three months of fiscal year 2019. The preliminary unaudited revenue of the Company for the period January to March 2019 was around EUR 6.8 million. This represents a revenue growth of approximately 46% compared to the previous year period, with pure product sales increasing by around 48%.
- GlobeNewswire
Biofrontera provides information on the announced voluntary public tender offer by Maruho Deutschland GmbH
Leverkusen, Germany, April 02, 2019 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, informs about.